News

Published on 17 Sep 2021 on Zacks via Yahoo Finance

Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12


Article preview image

Axsome Therapeutics, Inc. AXSM announced that it has initiated enrollment in the phase III study — SYMPHONY — which will evaluate its pipeline candidate, AXS-12, in patients with narcolepsy, a sleep disorder. Top-line data from the study is expected in 2023.

The company has successfully completed a phase II study evaluating the candidate in narcolepsy patients. Data from the mid-stage study demonstrated that treatment with AXS-12 resulted in a highly statistically significant reduction in the mean weekly number of cataplexy attacks from baseline compared to placebo, following a treatment period of two weeks. The treatment with AXS-12 also improved excessive daytime sleepiness by reducing the frequency of inadvertent naps in patients.

The candidate enjoys Orphan Drug Designation for the treatment of narcolepsy in the United States. However, the candidate lost its Breakthrough Therapy designation in July this year. The company stated that the FDA repealed the Breakthrough Therapy designation, following its approval to another drug, most likely Harmony Biosciences’ HRMY Wakix, as the first and only non-scheduled treatment for narcolepsy patients. We note that apart from Harmony Biosciences, Axsome will also face stiff competition from Jazz Pharmaceuticals JAZZ that has a strong sleep disorder portfolio with a couple of drugs approved to treat narcolepsy.

NASDAQ.AXSM price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday? - Axsome Therapeutics...

Monday, Axsome Therapeutics Inc AXSM released data from the SYMPHONY Phase 3 trial of AXS-12 (reb...

Benzinga 25 Mar 2024

Narcolepsy patients report high symptom persistence By Investing.com

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a company focused on developing therapies for central...

Investing.com 25 Mar 2024

AXS-12 shows promise in narcolepsy treatment, trial finds By Investing.com

Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company, announced today...

Investing.com 25 Mar 2024

Axsome Triumphs Over Major Depressive Disorder With Auvelity

Axsome Therapeutics Inc. (NASDAQ:AXSM) is a fast-growing pharmaceutical company headquartered in ...

GuruFocus.com via Yahoo Finance 22 Mar 2024

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

It was a busy week for the biotech sector with lots of study data readouts and regulatory approva...

Zacks via Yahoo Finance 21 Mar 2024

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Axsome Therapeutics, Inc. AXSM announced that it has dosed the first patient in the phase III PAR...

Zacks via Yahoo Finance 20 Mar 2024

Axsome commences phase 3 trial for depression drug By Investing.com

Axsome Therapeutics, Inc. (NASDAQ: NASDAQ:AXSM), a biopharmaceutical company focused on developin...

Investing.com 19 Mar 2024

Axsome therapeutics director sells over $2.2m in company stock By Investing.com

In a recent move, Roger Jeffs, a director at Axsome Therapeutics, Inc. (NASDAQ:AXSM), sold a...

Investing.com 15 Mar 2024

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

Axsome Therapeutics, Inc. AXSM reported an adjusted loss of 73 cents per share for the fourth qua...

Zacks via Yahoo Finance 21 Feb 2024

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript February 20, 2024 Axsome...

Insider Monkey via Yahoo Finance 21 Feb 2024